ContraFect Corporation - Product Pipeline Review

Global Markets Direct’s, ‘ContraFect Corporation - Product Pipeline Review - 2016’, provides an overview of the ContraFect Corporation’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by ContraFect Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of ContraFect Corporation

The report provides overview of ContraFect Corporation including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses ContraFect Corporation’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features ContraFect Corporation’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate ContraFect Corporation’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for ContraFect Corporation

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding ContraFect Corporation’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

ContraFect Corporation Snapshot 5

ContraFect Corporation Overview 5

Key Information ...

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

ContraFect Corporation Snapshot 5

ContraFect Corporation Overview 5

Key Information 5

Key Facts 5

ContraFect Corporation - Research and Development Overview 6

Key Therapeutic Areas 6

ContraFect Corporation - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

ContraFect Corporation - Pipeline Products Glance 11

ContraFect Corporation - Clinical Stage Pipeline Products 11

Phase I Products/Combination Treatment Modalities 11

ContraFect Corporation - Early Stage Pipeline Products 12

Preclinical Products/Combination Treatment Modalities 12

Discovery Products/Combination Treatment Modalities 13

ContraFect Corporation - Drug Profiles 14

CF-301 14

Product Description 14

Mechanism of Action 14

R&D Progress 14

CF-401 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

CF-402 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

CF-403 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

CF-404 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

Monoclonal Antibody 1 for Influenza 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

CF-302 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

CF-303 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

CF-304 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

CF-305 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

CF-306 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

CF-307 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

CF-308 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

CF-309 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

ContraFect Corporation - Pipeline Analysis 29

ContraFect Corporation - Pipeline Products by Target 29

ContraFect Corporation - Pipeline Products by Route of Administration 30

ContraFect Corporation - Pipeline Products by Molecule Type 31

ContraFect Corporation - Pipeline Products by Mechanism of Action 32

ContraFect Corporation - Recent Pipeline Updates 33

ContraFect Corporation - Dormant Projects 36

ContraFect Corporation - Locations And Subsidiaries 37

Head Office 37

Appendix 38

Methodology 38

Coverage 38

Secondary Research 38

Primary Research 38

Expert Panel Validation 38

Contact Us 38

Disclaimer 39

List of Tables

List of Tables

ContraFect Corporation, Key Information 5

ContraFect Corporation, Key Facts 5

ContraFect Corporation - Pipeline by Indication, 2016 7

ContraFect Corporation - Pipeline ...

List of Tables

ContraFect Corporation, Key Information 5

ContraFect Corporation, Key Facts 5

ContraFect Corporation - Pipeline by Indication, 2016 7

ContraFect Corporation - Pipeline by Stage of Development, 2016 9

ContraFect Corporation - Monotherapy Products in Pipeline, 2016 10

ContraFect Corporation - Phase I, 2016 11

ContraFect Corporation - Preclinical, 2016 12

ContraFect Corporation - Discovery, 2016 13

ContraFect Corporation - Pipeline by Target, 2016 29

ContraFect Corporation - Pipeline by Route of Administration, 2016 30

ContraFect Corporation - Pipeline by Molecule Type, 2016 31

ContraFect Corporation - Pipeline Products by Mechanism of Action, 2016 32

ContraFect Corporation - Recent Pipeline Updates, 2016 33

ContraFect Corporation - Dormant Developmental Projects,2016 36

List of Figures

List of Figures

ContraFect Corporation - Pipeline by Top 10 Indication, 2016 7

ContraFect Corporation - Pipeline by Stage of Development, 2016 9

ContraFect Corporation ...

List of Figures

ContraFect Corporation - Pipeline by Top 10 Indication, 2016 7

ContraFect Corporation - Pipeline by Stage of Development, 2016 9

ContraFect Corporation - Monotherapy Products in Pipeline, 2016 10

ContraFect Corporation - Pipeline by Target, 2016 29

ContraFect Corporation - Pipeline by Molecule Type, 2016 31

ContraFect Corporation - Pipeline Products by Top 10 Mechanism of Action, 2016 32

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports